Resumen de acción LH
Labcorp Holdings Inc. es una empresa de servicios de laboratorio que proporciona información vital para ayudar a médicos, hospitales, empresas farmacéuticas, investigadores y pacientes a tomar decisiones claras y seguras.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Recompensas
Análisis de riesgos
Competidores de Labcorp Holdings Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$196.36 |
| 52 Week High | US$243.30 |
| 52 Week Low | US$191.97 |
| Beta | 1.03 |
| 1 Month Change | -6.66% |
| 3 Month Change | -6.05% |
| 1 Year Change | -13.49% |
| 3 Year Change | -24.21% |
| 5 Year Change | 15.85% |
| Change since IPO | 705.58% |
Noticias y actualizaciones recientes
Here's Why It's Unlikely That Laboratory Corporation of America Holdings' (NYSE:LH) CEO Will See A Pay Rise This Year
May 08
Laboratory Corporation of America Holdings (NYSE:LH) Is Paying Out A Dividend Of $0.72
Apr 30Recent updates
Here's Why It's Unlikely That Laboratory Corporation of America Holdings' (NYSE:LH) CEO Will See A Pay Rise This Year
May 08Laboratory Corporation of America Holdings (NYSE:LH) Is Paying Out A Dividend Of $0.72
Apr 30Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72
Apr 15Laboratory Corporation of America Holdings' (NYSE:LH) P/E Is On The Mark
Apr 06Laboratory Corporation: A Healthier Diagnosis, As Pandemic Headwinds Disappear
Apr 01Laboratory Corporation of America Holdings (NYSE:LH) Will Pay A Dividend Of $0.72
Feb 25We Think You Can Look Beyond Laboratory Corporation of America Holdings' (NYSE:LH) Lackluster Earnings
Feb 22An Intrinsic Calculation For Laboratory Corporation of America Holdings (NYSE:LH) Suggests It's 48% Undervalued
Feb 21Laboratory Corporation of America Holdings (NYSE:LH) Has Affirmed Its Dividend Of $0.72
Jan 31Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly
Jan 30Laboratory Corporation of America Holdings' (NYSE:LH) Dividend Will Be $0.72
Jan 15Some Shareholders Feeling Restless Over Laboratory Corporation of America Holdings' (NYSE:LH) P/E Ratio
Jan 05Laboratory Corporation: Multiple Updates, Same Investment Conclusion
Dec 02Laboratory Corp.: Rate On Capital Deployed Contracting, Hold
Sep 14Laboratory Corporation: Trying To Create Value By Spinning Out Fortrea
Jul 05Newsflash: Laboratory Corporation of America Holdings (NYSE:LH) Analysts Have Been Trimming Their Revenue Forecasts
Jul 04Are Investors Undervaluing Laboratory Corporation of America Holdings (NYSE:LH) By 43%?
Jun 23Laboratory Corporation: Predictability Of Cash Flows Less Visible
Jun 21Is It Too Late To Consider Buying Laboratory Corporation of America Holdings (NYSE:LH)?
May 26Laboratory Corporation of America Holdings' (NYSE:LH) Returns On Capital Are Heading Higher
Mar 16Laboratory Corporation of America Holdings (NYSE:LH) Shares Could Be 32% Below Their Intrinsic Value Estimate
Mar 02Laboratory Corporation of America Non-GAAP EPS of $4.14 in-line, revenue of $3.7B misses by $40M, introduces FY23 outlook
Feb 16At US$254, Is It Time To Put Laboratory Corporation of America Holdings (NYSE:LH) On Your Watch List?
Jan 30Laboratory Corporation: Plenty Of Growth Runway
Jan 19Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly
Jan 16Laboratory Corporation of America declares $0.72 dividend
Jan 12Returns At Laboratory Corporation of America Holdings (NYSE:LH) Are On The Way Up
Dec 07Is There An Opportunity With Laboratory Corporation of America Holdings' (NYSE:LH) 25% Undervaluation?
Nov 24Laboratory Corporation: Buy Rating Holds Following Solid Mid-Level Growth
Nov 08Laboratory Corporation of America Q3 2022 Earnings Preview
Oct 26We Think Laboratory Corporation of America Holdings (NYSE:LH) Can Stay On Top Of Its Debt
Oct 14Rentabilidad de los accionistas
| LH | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | -0.8% | -1.5% | 1.0% |
| 1Y | -13.5% | 6.2% | 21.8% |
Rentabilidad vs. Industria: LH obtuvo unos resultados inferiores a los del sector US Healthcare , que el año pasado arrojó un rendimiento del 1%.
Rentabilidad vs. Mercado: LH obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.
Volatilidad de los precios
| LH volatility | |
|---|---|
| LH Average Weekly Movement | 2.8% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: LH no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LH (3%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 61,975 | Adam Schechter | www.labcorp.com |
Labcorp Holdings Inc. es una empresa de servicios de laboratorio que proporciona información vital para ayudar a médicos, hospitales, empresas farmacéuticas, investigadores y pacientes a tomar decisiones claras y seguras. Opera en dos segmentos, Diagnostics Laboratories (Dx) y Biopharma Laboratory Services (BLS). La empresa ofrece diversas pruebas, como análisis de química sanguínea, análisis de orina, recuentos de células sanguíneas, pruebas de tiroides, pruebas de PAP, hemoglobina A1C y vitamina D, antígenos prostáticos específicos, pruebas de enfermedades de transmisión sexual, pruebas de hepatitis C, cultivos y procedimientos microbiológicos, y pruebas de alcoholismo y otras pruebas de abuso de sustancias.
Resumen de fundamentos de Labcorp Holdings Inc.
| Estadísticas fundamentales de LH | |
|---|---|
| Capitalización bursátil | US$16.64b |
| Beneficios(TTM) | US$399.20m |
| Ingresos (TTM) | US$12.30b |
41.5x
Ratio precio-beneficio (PE)1.3x
Ratio precio-ventas (PS)¿Está LH sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de LH | |
|---|---|
| Ingresos | US$12.30b |
| Coste de los ingresos | US$8.89b |
| Beneficio bruto | US$3.41b |
| Otros gastos | US$3.01b |
| Beneficios | US$399.20m |
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 4.74 |
| Margen bruto | 27.74% |
| Margen de beneficio neto | 3.25% |
| Ratio deuda/patrimonio | 64.8% |
¿Cómo se ha desempeñado LH a largo plazo?
Ver rendimiento histórico y comparativa